Home > Boards > US Listed > Biotechs > Gamida Cell Ltd. (GMDA)

Hi top123. i womder if you read this:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 120
Posts 25,359
Boards Moderated 8
Alias Born 02/07/04
160x600 placeholder
Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference Business Wire - 4/7/2021 8:00:00 AM
Gamida Cell Presents Efficacy & Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at th... Business Wire - 3/15/2021 10:24:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/11/2021 4:36:22 PM
Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) Edgar (US Regulatory) - 3/11/2021 4:02:23 PM
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 3/11/2021 3:34:31 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 3/11/2021 6:04:18 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/9/2021 4:09:39 PM
Gamida clibs 5.6% despite a Q4 miss, provides 2021 guidance Seeking Alpha - 3/9/2021 11:22:41 AM
Gamida Cell EPS misses by $0.35; outlook Seeking Alpha - 3/9/2021 7:05:01 AM
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update Business Wire - 3/9/2021 7:00:00 AM
Gamida Cell to Present at Upcoming Investor Conferences Business Wire - 3/3/2021 7:00:00 AM
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast Business Wire - 3/2/2021 7:00:00 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 3/1/2021 4:40:43 PM
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Soc... Business Wire - 3/1/2021 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/26/2021 3:13:08 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/17/2021 3:11:52 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/16/2021 2:22:05 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/16/2021 8:58:20 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 8:30:16 AM
Gamida Cell launches $75M financing with Highbridge Capital Management Seeking Alpha - 2/16/2021 8:04:19 AM
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management Business Wire - 2/16/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 5:53:48 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 4:46:15 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2021 3:13:10 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/10/2021 4:02:17 PM
midastouch017   Wednesday, 02/17/21 12:58:23 PM
Re: top123 post# 273
Post # of 297 
Hi top123. i womder if you read this:

Omidubicel, also known as NiCord, has been developed using the company's proprietary nicotinamide (NAM) cell-expansion platform technology, which is used to increase both the number and efficacy of any type of donor cells. In addition to being a superior treatment option over the currently available umbilical cord blood transplant, omidubicel can also offer an off-the-shelf treatment option to around 5,200 blood cancer patients who are eligible for a bone marrow transplant, yet unable to undergo it due to low availability of matching donors. Within three years from its launch, the company expects omidubicel to treat around 2,000 U.S. patients annually and capture 20% share of the bone marrow transplantation market, which is estimated to be worth $13.9 billion by 2026. #msg-161885562

Quote:
If that article numbers are correct, what SP numbers are we looking at



I would estimate company m/c of $1.5-2billion, sp should be in
the area of ~$30-35

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences